mitindomide has been researched along with icrf 193 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allan, WP; Creighton, AM; Hasinoff, BB; Kozlowska, H; Thampatty, P; Yalowich, JC | 1 |
| Jensen, LH; Jensen, PB; Nitiss, JL; Renodon-Cornière, A; Sehested, M; Søkilde, B; Sørensen, TK | 1 |
2 other study(ies) available for mitindomide and icrf 193
| Article | Year |
|---|---|
Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site.
Topics: Animals; Antineoplastic Agents; CHO Cells; Cricetinae; Diketopiperazines; DNA; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Indoles; Isoindoles; Piperazines; Razoxane; Topoisomerase II Inhibitors | 1997 |
Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha.
Topics: Adenosine Triphosphate; Antigens, Neoplasm; Catalysis; Diketopiperazines; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Genetic Complementation Test; Humans; Indoles; Isoindoles; Mutagenesis, Site-Directed; Piperazines; Razoxane; Topoisomerase II Inhibitors; Yeasts | 2003 |